Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + SOX
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Adebrelimab + SOX** is a combination therapy being investigated primarily for the treatment of gastric adenocarcinoma, esophageal cancer, and related malignancies. Adebrelimab is a monoclonal antibody that inhibits programmed cell death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses[7][10]. The SOX regimen consists of two chemotherapeutic agents: oxaliplatin and an oral fluoropyrimidine combination (gimeracil/oteracil/tegafur, also known as S-1)[1][3][5]. The combination aims to improve pathological response rates and overall survival by combining immunotherapy with cytotoxic chemotherapy[1][8][10]. Clinical trials are ongoing in the adjuvant and neoadjuvant treatment settings for locally advanced or resectable gastric and gastroesophageal cancers.
- Brand names
- Ariely
- Other names
- adebrelimab + SOX
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)DNAOPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on adebrelimab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + SOX.